Fluor Corporation (FLR) announced that its Advanced Technologies & Life Sciences business was selected by Agilent Technologies (A) to expand its oligonucleotide therapeutics manufacturing facility in Frederick, Colorado, just north of Denver. Fluor is supporting engineering and procurement as part of the project. The total project value is $725M. "Speed to market is essential in the pharmaceutical industry," said Juan Hernandez, president of Fluor’s Advanced Technologies & Life Sciences business. "We will incorporate state-of-the-art engineering enhancements such as advanced automation, water reduction strategies and solvent capturing to optimize cost and construction. This enables us to fast-track the project so that Agilent can meet its global customers’ needs by getting products to market faster."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on FLR: